Funding Rounds
Hemab

Hemab Series B (2023, $135M)

Hemab

Treatments for genetic bleeding disorders.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series B

Raised Amount: $135.00M